Treatment of HER2-positive breast cancer: Current status and future perspectives

Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni

Research output: Contribution to journalArticle

476 Citations (Scopus)

Abstract

The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-positive early stage breast cancer. However, a significant proportion of these patients still relapse and die of breast cancer. Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing. In addition, promising new approaches are being developed including monoclonal antibodies and small-molecule tyrosine kinase inhibitors targeting HER2 or other HER family members, antibodies linked to cytotoxic moieties or modified to improve their immunological function, immunostimulatory peptides, and targeting the PI3K and IGF-1R pathways. Improved understanding of the HER2 signaling pathway, its relationship with other signaling pathways and mechanisms of resistance has also led to the development of rational combination therapies and to a greater insight into treatment response in patients with HER2-positive breast cancer. Based on promising results with new agents in HER2-positive advanced-stage disease, a series of large trials in the adjuvant and neoadjuvant settings are planned or ongoing. This Review focuses on current treatment for patients with HER2-positive breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clinical trials and translational research.

Original languageEnglish (US)
Pages (from-to)16-32
Number of pages17
JournalNature Reviews Clinical Oncology
Volume9
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Breast Neoplasms
Therapeutics
Translational Medical Research
Phosphatidylinositol 3-Kinases
Protein-Tyrosine Kinases
Monoclonal Antibodies
Clinical Trials
Recurrence
Peptides
Antibodies

ASJC Scopus subject areas

  • Oncology

Cite this

Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012). Treatment of HER2-positive breast cancer: Current status and future perspectives. Nature Reviews Clinical Oncology, 9(1), 16-32. https://doi.org/10.1038/nrclinonc.2011.177

Treatment of HER2-positive breast cancer : Current status and future perspectives. / Arteaga, Carlos L.; Sliwkowski, Mark X.; Osborne, C. Kent; Perez, Edith A.; Puglisi, Fabio; Gianni, Luca.

In: Nature Reviews Clinical Oncology, Vol. 9, No. 1, 01.2012, p. 16-32.

Research output: Contribution to journalArticle

Arteaga, CL, Sliwkowski, MX, Osborne, CK, Perez, EA, Puglisi, F & Gianni, L 2012, 'Treatment of HER2-positive breast cancer: Current status and future perspectives', Nature Reviews Clinical Oncology, vol. 9, no. 1, pp. 16-32. https://doi.org/10.1038/nrclinonc.2011.177
Arteaga, Carlos L. ; Sliwkowski, Mark X. ; Osborne, C. Kent ; Perez, Edith A. ; Puglisi, Fabio ; Gianni, Luca. / Treatment of HER2-positive breast cancer : Current status and future perspectives. In: Nature Reviews Clinical Oncology. 2012 ; Vol. 9, No. 1. pp. 16-32.
@article{765cd25cb03c456ba40bd81a1d2c0c91,
title = "Treatment of HER2-positive breast cancer: Current status and future perspectives",
abstract = "The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-positive early stage breast cancer. However, a significant proportion of these patients still relapse and die of breast cancer. Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing. In addition, promising new approaches are being developed including monoclonal antibodies and small-molecule tyrosine kinase inhibitors targeting HER2 or other HER family members, antibodies linked to cytotoxic moieties or modified to improve their immunological function, immunostimulatory peptides, and targeting the PI3K and IGF-1R pathways. Improved understanding of the HER2 signaling pathway, its relationship with other signaling pathways and mechanisms of resistance has also led to the development of rational combination therapies and to a greater insight into treatment response in patients with HER2-positive breast cancer. Based on promising results with new agents in HER2-positive advanced-stage disease, a series of large trials in the adjuvant and neoadjuvant settings are planned or ongoing. This Review focuses on current treatment for patients with HER2-positive breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clinical trials and translational research.",
author = "Arteaga, {Carlos L.} and Sliwkowski, {Mark X.} and Osborne, {C. Kent} and Perez, {Edith A.} and Fabio Puglisi and Luca Gianni",
year = "2012",
month = "1",
doi = "10.1038/nrclinonc.2011.177",
language = "English (US)",
volume = "9",
pages = "16--32",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Treatment of HER2-positive breast cancer

T2 - Current status and future perspectives

AU - Arteaga, Carlos L.

AU - Sliwkowski, Mark X.

AU - Osborne, C. Kent

AU - Perez, Edith A.

AU - Puglisi, Fabio

AU - Gianni, Luca

PY - 2012/1

Y1 - 2012/1

N2 - The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-positive early stage breast cancer. However, a significant proportion of these patients still relapse and die of breast cancer. Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing. In addition, promising new approaches are being developed including monoclonal antibodies and small-molecule tyrosine kinase inhibitors targeting HER2 or other HER family members, antibodies linked to cytotoxic moieties or modified to improve their immunological function, immunostimulatory peptides, and targeting the PI3K and IGF-1R pathways. Improved understanding of the HER2 signaling pathway, its relationship with other signaling pathways and mechanisms of resistance has also led to the development of rational combination therapies and to a greater insight into treatment response in patients with HER2-positive breast cancer. Based on promising results with new agents in HER2-positive advanced-stage disease, a series of large trials in the adjuvant and neoadjuvant settings are planned or ongoing. This Review focuses on current treatment for patients with HER2-positive breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clinical trials and translational research.

AB - The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-positive early stage breast cancer. However, a significant proportion of these patients still relapse and die of breast cancer. Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing. In addition, promising new approaches are being developed including monoclonal antibodies and small-molecule tyrosine kinase inhibitors targeting HER2 or other HER family members, antibodies linked to cytotoxic moieties or modified to improve their immunological function, immunostimulatory peptides, and targeting the PI3K and IGF-1R pathways. Improved understanding of the HER2 signaling pathway, its relationship with other signaling pathways and mechanisms of resistance has also led to the development of rational combination therapies and to a greater insight into treatment response in patients with HER2-positive breast cancer. Based on promising results with new agents in HER2-positive advanced-stage disease, a series of large trials in the adjuvant and neoadjuvant settings are planned or ongoing. This Review focuses on current treatment for patients with HER2-positive breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clinical trials and translational research.

UR - http://www.scopus.com/inward/record.url?scp=84655162706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84655162706&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2011.177

DO - 10.1038/nrclinonc.2011.177

M3 - Article

C2 - 22124364

AN - SCOPUS:84655162706

VL - 9

SP - 16

EP - 32

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 1

ER -